Cytomx Therapeutics Stock Investor Sentiment

CTMX Stock  USD 1.06  0.04  3.92%   
Slightly above 57% of all CytomX Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding CytomX Therapeutics suggests that some traders are interested. CytomX Therapeutics' investing sentiment can be driven by a variety of factors including economic data, CytomX Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

CytomX Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards CytomX Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at news.google.com         
CytomX Therapeutics Loses -13.45 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Co...
Google News at Macroaxis
over three months ago at simplywall.st         
CytomX Therapeutics, Inc.s latest 11 percent decline adds to one-year losses, institutional investor...
Simply Wall St News at Macroaxis
over three months ago at www.macroaxis.com         
Acquisition by Christopher Ogden of 75000 shares of CytomX Therapeutics at 1.49 subject to Rule 16b-...
Macroaxis News
over three months ago at www.macroaxis.com         
Acquisition by Christopher Ogden of 40000 shares of CytomX Therapeutics subject to Rule 16b-3
Macroaxis News
over three months ago at news.google.com         
Heres Why CytomX Therapeutics is a Great Momentum Stock to Buy - Yahoo New Zealand News
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Shareholders in CytomX Therapeutics are in the red if they invested five years ago
Yahoo News
over three months ago at news.google.com         
CytomX Therapeutics, Inc. Receives Consensus Recommendation of Moderate Buy from Brokerages - Defens...
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Young Matthew P. of 38000 shares of CytomX Therapeutics at 1.96 subject to Rule 16b-3
Macroaxis News
over six months ago at investorplace.com         
No Memes, Maam Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
sbwire news
over six months ago at news.google.com         
Piper Sandler upgrades CytomX Therapeutics stock, cites promising data By Investing.com - Investing....
Google News at Macroaxis
over six months ago at globenewswire.com         
Disposition of 1477 shares by Landau Jeffrey B of CytomX Therapeutics at 1.9792 subject to Rule 16b-...
Macroaxis News: globenewswire.com
over six months ago at www.macroaxis.com         
Acquisition by Marcia Belvin of 26250 shares of CytomX Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Ashworth Alan of 38000 shares of CytomX Therapeutics at 1.96 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Chu Yu-waye of 26250 shares of CytomX Therapeutics subject to Rule 16b-3
Macroaxis News
over six months ago at benzinga.com         
Analysts Varied Perspectives On CytomXs CX-904 Cancer Study Safety Profile But Caution in Pancreatic...
benzinga news
Far too much social signal, news, headlines, and media speculation about CytomX Therapeutics that are available to investors today. That information is available publicly through CytomX media outlets and privately through word of mouth or via CytomX internal channels. However, regardless of the origin, that massive amount of CytomX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytomX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytomX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytomX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytomX Therapeutics alpha.

CytomX Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Marcia Belvin of 60000 shares of CytomX Therapeutics subject to Rule 16b-3
09/23/2024
2
Disposition of 16535 shares by Mccarthy Sean A. of CytomX Therapeutics at 1.5749 subject to Rule 16b-3
10/14/2024
3
Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer
10/23/2024
4
Earnings To Watch CytomX Therapeutics Inc Reports Q3 2024 Result
11/06/2024
5
CytomX Therapeutics Q3 Earnings and Revenues Top Estimates
11/07/2024
6
CytomX Therapeutics Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth Amid ...
11/08/2024
7
CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment
11/12/2024
8
Biotechnology Value Fund L P Increases Stake in CytomX Therapeutics Inc
11/15/2024
9
CHMP Endorses AstraZenecas Tagrisso for Expanded Use in NSCLC
11/19/2024
10
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
11/21/2024

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.